Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
There is not a significant difference in three-year liver cancer survival rates between people living with HIV and people who are not.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
They also have a higher rate of death from cancer after receiving a diagnosis.
HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
Being diagnosed with liver cancer at a later stage of the disease was associated with a lower three-year survival rate.
A European study of nearly 19,000 people with HIV also found that curing hep C was not associated with heart disease or non-AIDS cancer.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Those who exercise build up less liver fat, which is tied to inflammation that may give rise to cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.